Prostate

Papers
(The H4-Index of Prostate is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
The role of PSMA PET/CT to predict upgrading in patients undergoing radical prostatectomy for ISUP grade group 1 prostate cancer58
50
Impact of androgen receptor alterations on cell‐free DNA genomic profiling on survival outcomes in metastatic castration‐resistant prostate cancer41
Continuity of care in acute survivorship phase, and short and long‐term outcomes in prostate cancer patients40
Rates of metastatic prostate cancer in newly diagnosed patients: Numbers needed to image according to risk level38
Prognostic value of circulating tumor cells in oligorecurrent hormone‐sensitive prostate cancer patients undergoing stereotactic body radiation therapy35
Incidental Brain Metastases From Prostate Cancer Diagnosed With PSMA PET/CT and MRI: A Case Series and Literature Review35
VOC‐based detection of prostate cancer using an electronic nose and ion mobility spectrometry: A novel urine‐based approach25
Comprehensive Genomic Profiling Testing for Castration‐Resistant Prostate Cancer in Advanced Elderly Patients: A Single‐Center Retrospective Cohort Study23
Prognostic factors of overall and prostate‐specific antigen‐progression‐free survival in metastatic castration‐resistant prostate cancer patients treated with 177Lu‐PSMA‐617. A single‐cente23
22
3βHSD activity saturates at physiological substrate concentrations in intact cells21
21
Association of plasma NRP2 and VEGF‐C levels with prostate cancer disease severity20
Real‐world study: Impact of multidisciplinary management of apalutamide‐associated adverse events in prostate cancer19
A panel‐based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration‐resistant prostate cancer19
βArrestin1 regulates glucocorticoid receptor mitogenic signaling in castration‐resistant prostate cancer19
Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone‐sensitive prostate cancer: A multicenter study18
Tumorigenic transformation of human prostatic epithelial cell line RWPE‐1 by growth hormone‐releasing hormone (GHRH)18
Analysis of three primary prostatic sarcoma cases and literature review18
Strong PD‐L1 expression in granulomatous prostatitis18
Delivery of antisense oligonucleotides for splice‐correction of androgen receptor pre‐mRNA in castration‐resistant prostate cancer models using cell‐penetrating peptides18
0.071991920471191